Core Viewpoint - The company has established a wholly-owned subsidiary in the Qianhai Free Trade Zone, Shenzhen, with a registered capital of up to 22 million yuan, focusing on human genetic diagnosis and treatment technology development [1] Group 1 - The board meeting was held in January 2026 to approve the establishment of the subsidiary [1] - The newly formed subsidiary is named Xinlitai Life Sciences (Shenzhen) Co., Ltd. and has completed its business registration [1] - The legal representative of the subsidiary is Xu Wenjie [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its injectable penicillin sodium, indicating successful compliance with the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The injectable penicillin sodium is approved in a dosage of 0.96g (1.6 million units) [1] - This medication is indicated for various infections caused by sensitive bacteria, including abscesses, bacteremia, pneumonia, and endocarditis [1]

经济观察网山河药辅公告通过美国食品药品监督管理局(FDA)现场检查，核查涵盖质量、生产等六大体 系。该事件标志着公司产品质量体系接轨国际，对拓展美国及全球市场有积极影响。 近期事件 经济观察网山河药辅公告通过美国食品药品监督管理局(FDA)现场检查，核查涵盖质量、生产等六大体 系。该事件标志着公司产品质量体系接轨国际，对拓展美国及全球市场有积极影响。 近期事件 2026年2月4日，山河药辅公告通过美国食品药品监督管理局(FDA)现场检查，核查涵盖质量、生产等六 大体系。该事件标志着公司产品质量体系接轨国际，对拓展美国及全球市场有积极影响。 股票近期走势 近7天(2026年2月4日至11日)，山河药辅股价呈现波动态势。2月5日股价触及阶段高点17.14元，随后回 调；截至2月11日最新收盘价15.98元，单日上涨0.50%，换手率5.12%。资金流向方面，2月10日主力资 金净流出198.98万元，但游资和散户资金分别净流入157.36万元和41.62万元，显示市场活跃度维持。技 术面显示，股价短期处于多头行情，20日压力位16.68元，支撑位14.53元。 以上内容基于公开资料整理，不构成投资建议。 2026 ...

近期事件 公司公告副总经理张晖因到龄退休辞职，其持有公司股份将依法管理。此次人事变动属正常退休，对日 常经营影响有限。 以上内容基于公开资料整理，不构成投资建议。 经济观察网公司2025年度业绩预告显示，预计归母净利润亏损3.5亿元至4.3亿元，较2024年大幅收窄； 营业收入预计8亿元至9亿元。亏损收窄主要因销售费用减少、信用减值损失减少等非经常性因素。该预 告反映公司亏损压力有所缓解，但受医保集采政策、创新药未上市等因素影响，持续亏损风险仍存。 股票近期走势 近7日，公司股价震荡下跌，截至2月11日收盘价6.30元，累计跌幅1.56%。融资余额占流通市值比例较 高，资金流向显示主力资金净流出，市场交投活跃度一般。 ...

格隆汇2月11日丨常山药业(300255.SZ)在投资者互动平台表示，艾本那肽尚未完成审评。 ...

Group 1 - Yunnan Baiyao plans to invest 137 million yuan in the second phase of its oral liquid project to meet growing market demand for its products [1] - Hanma Technology's subsidiary intends to increase capital by 575 million yuan in Shanghai Suoda and transfer 100% of its shares for 485 million yuan [2] - JiaoKong Technology won a contract worth 16.8 million euros for a project in Turkey, expected to be operational by December 2028 [3] Group 2 - Hanhui Technology's shareholder plans to reduce their stake by up to 1.86% [4] - Haisheng Pharmaceutical reported a 32.72% increase in revenue and a 36.89% increase in net profit for 2025 [5] - Oukang Pharmaceutical's net profit for 2025 decreased by 48.21% despite a 7.73% increase in revenue [6] Group 3 - Huaihe Energy expects a net profit of 1.684 to 1.784 billion yuan for 2025, a year-on-year increase of 96.31% to 107.97% [7] - Watson Bio received approval for clinical trials of its varicella vaccine [8] - ShunNa Co. plans to reduce its stake by up to 1% [9] Group 4 - Chutianlong intends to raise up to 760 million yuan through a private placement [10] - Yifang Technology's shareholders plan to reduce their holdings by up to 34,830 shares [12] - Yunjigroup's subsidiary signed an EPC contract worth 1.331 billion yuan [13] Group 5 - Jianghuai Automobile reported a 2.14% decrease in January sales [15] - Lifan Pharmaceutical participated in a national procurement program and aims to be selected for three products [16] - Magu Technology's shareholder plans to reduce their stake by up to 3% [17] Group 6 - Jianghuai Automobile's private placement raised approximately 3.5 billion yuan, with investor Ge Weidong subscribing for 1 billion yuan [18] - Huichuan Technology expects a net profit increase of 16% to 26% for 2025 [19] - Hezhong China reported a 10.24% decrease in January consolidated revenue [20] Group 7 - Zhongjian Technology plans to invest 30 million yuan in a new fund focused on new energy [22] - Kanda New Materials intends to invest 646 million yuan in a new production project [23] - Yuegui Co.'s subsidiary obtained a mining license [25] Group 8 - TBG Technology plans to invest 1.53 billion yuan in a new project [27] - Xiexin Integration stated it currently lacks production capacity in the "space photovoltaic" sector [28] - Shibao Testing's controlling shareholder plans to transfer 8.5% of the company's shares [29] Group 9 - TeBao Bio reported a 31.18% increase in revenue and a 25.39% increase in net profit for 2025 [30] - Guoke Tiancai reported a 14.73% increase in revenue and a 17.94% increase in net profit for 2025 [31] - Miaokelando signed a memorandum with SADAFCO to explore the children's cheese snack market in Saudi Arabia [32] Group 10 - Tangrenshen reported a 25.6% decrease in January sales revenue [33] - Northeast Securities received approval to establish a subsidiary in Hong Kong [34] - Yiyi Co. terminated its asset acquisition plan due to changes in the target company's performance [35] Group 11 - Wushang Group's major shareholder plans to reduce their stake by up to 3% [36] - Weigang Technology's shareholder plans to reduce their stake by up to 2.98% [37] - Yutong Technology plans to acquire 51% of Huayan Technology for 449 million yuan [38] Group 12 - Huasan Pharmaceutical's shareholder plans to reduce their stake by up to 3% [39] - Runbei Hangke's major shareholder plans to reduce their stake by up to 3% [41] - Huada Technology plans to acquire 100% of Huayi Microelectronics for 2.996 billion yuan [42] Group 13 - ST Lifang's stock will resume trading after completing self-inspection work [43]

Clarification Response - ST Xinhua Jin is facing potential suspension risk as the deadline for rectifying fund occupation approaches [1] - Hengdian Film's stock has risen significantly, but the box office for upcoming films like "Fast and Furious 3" remains uncertain, and AI short drama business is still in the investment stage without revenue [1] - Baichuan Co. reports a rise in market prices for some main products, but the impact on company performance is currently unpredictable [1] - Dinggu Creative's 5.8018% stake in Hangju Technology is a financial investment and will not significantly affect operational performance [1] - Jiamei Packaging may apply for suspension again if stock prices rise abnormally [1] - Lande Co. has only achieved small batch supply in its gas turbine business, with limited impact on performance [1] - Dawi Technology's Zhangbei data center project does not involve core computing leasing business [1] - Runtu Co. cannot currently predict the impact of price fluctuations in disperse dyes on company performance [1] - Changfei Fiber's products for data centers account for a small proportion of global market demand [1] - GCL-Poly does not yet have production capabilities for "space photovoltaic" products and has not received relevant orders [1] - Guansheng Co.'s robotics products currently have no orders and have not generated revenue [1] Shareholding Reduction - Yandong Micro has seen the National Integrated Circuit Industry Investment Fund reduce its stake to 5%, no longer a major shareholder [1] - Huason Pharmaceutical's shareholder Liu Xiaoying plans to reduce holdings by up to 3% [1] - Runbei Aerospace's shareholders plan to collectively reduce holdings by up to 3% [1] - Wushang Group's shareholder Dazi Yintai intends to reduce holdings by up to 3% [1] - Haitai Technology's controlling shareholder Sun Wenqiang plans to reduce holdings by up to 3% [1] - Weigang Technology's shareholder Pingyang Weishi Investment intends to reduce holdings by up to 2.98% [1] - Wangsu Technology's director Liu Chengyan plans to reduce holdings by up to 1.07% [1] - Hunan Silver (core stock) has completed a 1% share reduction by Chenzhou Guokong [1] Performance - Kerryde is projected to incur a net loss of 22.18 million yuan in 2025 [1]

Core Viewpoint - The announcement details the change of the sponsor representative for the ongoing supervision of the initial public offering (IPO) of Chenxin Pharmaceutical Co., Ltd. by Zhongtai Securities Co., Ltd. [1] Group 1: Change of Sponsor Representative - Zhongtai Securities has appointed Suo Jianpeng as the new sponsor representative to replace Zeng Liping, who has been reassigned to other responsibilities [1] - The ongoing supervision will continue until the obligations set by the China Securities Regulatory Commission and the Shanghai Stock Exchange are fulfilled [1] Group 2: Acknowledgment of Contributions - The board of directors expresses gratitude for Zeng Liping's contributions during her tenure as the sponsor representative [2] Group 3: Background of New Representative - Suo Jianpeng is the Vice President of the Investment Banking Business Committee at Zhongtai Securities and has previously participated in various IPO projects [3]

Group 1 - The company, SiHuan Pharmaceutical (00460.HK), expects to achieve revenue of no less than RMB 2.5 billion for the fiscal year ending December 31, 2025, representing a growth rate of over 30% compared to the same period last year [1] - The anticipated net profit for the same fiscal year is projected to be no less than RMB 150 million [1] - As of February 10, 2026, SiHuan Pharmaceutical's stock closed at HKD 1.67, down 1.76%, with a trading volume of 46.33 million shares and a turnover of HKD 78.42 million [1] Group 2 - The stock is primarily rated as a "buy" by investment banks, with two firms issuing buy ratings in the last 90 days [1] - The average target price for the stock over the past 90 days is HKD 1.6 [1] - Guohai Securities has recently issued a buy rating for SiHuan Pharmaceutical [1] Group 3 - SiHuan Pharmaceutical has a market capitalization of HKD 15.548 billion and ranks 10th in the chemical pharmaceutical industry [1]

Group 1 - The JPM 2026 conference revealed innovative opportunities in the pharmaceutical and medical device sectors, particularly in the IO plus field where the trend of using VEGF dual antibodies in multiple indications is becoming established [1] - There is a focus on multinational corporations (MNCs) and leading biotech companies developing dual antibodies and combinations with monoclonal antibodies targeting other immune-related sites [1] - In the ADC (Antibody-Drug Conjugate) area, attention is drawn to first-in-class (FIC) products for large indications, new indications for major products, and advancements in dual toxin/new toxin ADC technologies, which are leading directions for domestic innovative drugs [1] Group 2 - The ETF Guotai (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20%, and selects listed companies engaged in biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services [2] - The index emphasizes the R&D investment and technological leadership of constituent companies, focusing on high-growth potential in the pharmaceutical health sector [2] - The ETF aims to reflect the overall performance of listed companies related to innovative biopharmaceuticals [2]